Parkinson´s Disease

The reduction in dyskinesia is one of the most valued effects in patients with Parkinson's Disease. The results of the studies suggest that cannabinoids may offer some benefit due to their improvement in motor function as well as a neuroprotective effect.

Medical Cannabis’ effects on Parkinson’s Disease:

  • Reduction of dyskinesia.
  • Neuroprotective effect.
  • Antipsychotic.
  • Improvement in motor function.

Parkinson’s Disease is a degenerative disease that mainly affects the central nervous system. At the cellular level, it is characterized by the destruction of the dopamine-producing cells, an essential neurotransmitter for motor function, causing involuntary movements known as dyskinesia, among others.

The dopamine-producing cells are located in the reticulated part of the substantia nigra, an area where the cannabinoid receptors are also grouped. Due to this, CBD is attributed to having therapeutic effects, since it reduces the dyskinesia induced by L-DOPA, relieves body stiffness and allows greater motor control overall. That is why patients treated with cannabidiol report a great improvement in their quality of life.

The current treatment used in traditional medicine can lead to side effects such as dementia, depression and cognitive deterioration. However, clinical trials have shown the effectiveness of cannabinoids as a treatment for Parkinson’s Disease without producing disorders that derive from traditional medication, where their findings aim to improve the quality of life through the use of CBD without psychiatric effects.

Also, other trials claim that there is scientific evidence that cannabinoids have a therapeutic value in some disorders associated with movement due to the reduction of dyskinesia, some forms of tremor and dystonia induced by L-DOPA in Parkinson’s Disease, and could contribute to decreasing tics in Tourette’s syndrome and hypokinetic parkinsonian syndromes.


Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics, October 2015, Volume 12, Issue 4, pp 788–79.
Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience, 2017. Balash, Yacov; Bar-Lev Schleider, Lihi; Korczyn, Amos D.; Shabtai, Herzel; Knaani, Judith; Rosenberg, Alina; Baruch, Yehuda; Djaldetti, Ruth; Giladi, Nir; Gurevich, Tanya MD.
Neurological Disorders in Medical Use of Cannabis: An Update, 2017. Solimini, Renata; Rotolo, Maria C.; Pichini, Simona; Pacifici, Roberta.
Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting, 2017. Mary Barna Bridgeman, PharmD, BCPS, BCGP and Daniel T. Abazia, PharmD, BCPS, CPE.
Practical considerations in medical cannabis administration and dosing, 2018. Caroline A. MacCallum; Ethan B.Russo.

See more diseases

See more